American Society of Hematology

Figure 1.

(A) PFS in Mayo Clinic patients with DLBCL-RS by prior CLL treatment status. Used with the permission of Wang et al.14 (B) PFS in patients in a case series according to the presence or absence of T53 mutation/deletion. (C) PFS of patients in a case series by clonal relationship to the underlying CLL. (B) and (C) used with the permission of Rossie et al.8 RT, Richter’s transformation.

(A) PFS in Mayo Clinic patients with DLBCL-RS by prior CLL treatment status. Used with the permission of Wang et al.¹⁴ (B) PFS in patients in a case series according to the presence or absence of T53 mutation/deletion. (C) PFS of patients in a case series by clonal relationship to the underlying CLL. (B) and (C) used with the permission of Rossie et al.⁸ RT, Richter’s transformation.

This Feature Is Available To Subscribers Only